Case Report

Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin

Table 1

Laboratory results at the start of SOF/RBV combination therapy (2015/9).

CBC
WBC3.4×103/μL
RBC3.3×106/μL
Hb10.4g/dL
Hct29.9%
MCV90.6fL
Plt159×103/μL
Reticulocyte1.37%
Coagulation
PT81%

Tumor marker
AFP3.6ng/mL
PIVKA-II18mAU/mL

HCV viral marker
HCV RNA6.14
HCV genotype2b
Biochemistry
TP7.2g/dL
Alb4.2g/dL
Ferritin98ng/ml
T-Bil0.9mg/dL
D-Bil0.1U/L
ID-Bil0.8U/L
AST37U/L
ALT26U/L
LDH227U/L
ALP134U/L
γ-GTP13U/L
BUN10.9mg/dL
Cr0.63mg/dL
eGFR69.1ml/min/1.73 m2
T-chol199mg/dL

IL-28B genotypeTT
(rs8099917)
ITPAC/A
(rs7270101)

FIB-4 index3.38
Fibro scan4.3Kpa (F0 level)
CAP206dB/m (S0 level)

Height148cm
Weight49.8kg

Transient elastography (Fibroscan®). CAP: controlled attenuation parameter.